MarginsXMarginsX
Home › Markets › Health Care › CRL

Charles River Laboratories International Inc. (CRL)

CRL trades on NYSE in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$335.52
-0.72% on the day
Market cap
$16.1B
Large cap
Revenue · 2025
$4.0B
-0.9% on 2024
Net income · 2025
-$144.3M
-3.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-27, https://www.sec.gov/Archives/edgar/data/1100682/000110068226000022/0001100682-26-000022-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-27.

Profile

FieldValue
TickerCRL on NYSE
SectorHealth Care
IndustryBiotechnology: Commercial Physical & Biological Resarch
CountryUnited States
IPO year2000
SEC CIK0001100682
SEC industry codeServices-Commercial Physical & Biological Research

Financials · 2025

LineValue
Revenue$4.0B
Net income-$144.3M
Operating income$25.2M
Net margin-3.6%
Operating margin0.6%
Revenue growth-0.9%
Cash$213.8M
Total assets$7.1B
P/E (computed)Net income was not positive
P/S (computed)4.0×

Warning signs

Cash runway
Cash-flow positive
$200.4M cash at September 26, 2026
Share count, 1 year
-2.6%
2025-10-25 to 2026-10-24 · -6.6% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$42.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$200.4M cash; operating cash flow $155.6M a quarter.Report 2026-09-26
Shares outstanding47,917,467 (2026-10-24); 49,215,471 a year earlier; 51,296,804 three years earlier.Cover page 2026-10-24
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $4K, sold $42.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-26
$982.7M$333.1M$254.1M$200.4M$2.4B$4.0B10-Q 2026-11-04
Q2 2026
2026-06-27
$1.0B-$1.5M$179.7M$192.0M$2.6B$4.0B10-Q 2026-08-05
Q1 2026
2026-03-28
$995.8M-$14.8M$41.1M$191.8M$2.7B$4.0B10-Q 2026-05-07
Q4 2025
2025-12-27
$994.2M-$276.6M$147.5M$213.8M$2.1B$4.0B10-K 2026-02-18
Q3 2025
2025-09-27
$1.0B$54.4M$213.8M$207.1M$2.2B$4.0B10-Q 2026-11-04
Q2 2025
2025-06-28
$1.0B$52.3M$204.6M$182.8M$2.3B$4.0B10-Q 2026-08-05
Q1 2025
2025-03-29
$984.2M$25.5M$171.7M$229.4M$2.5B$4.0B10-Q 2026-05-07
Q4 2024
2024-12-28
$1.0B-$214.5M$159.4M$194.6M$2.2B$4.0B10-K 2026-02-18

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3ASR
S-3ASR2024-05-09
Latest annual report10-K2026-02-18
Latest quarterly / interim10-Q2026-11-04
Latest current report
FORM 8-K
8-K2026-11-09
Latest proxyDEF 14A2026-03-31

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.1%
1 month+13.0%
3 months+20.2%
Year to date+69.4%
1 year+99.7%
From 52-week high-10.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Commercial Physical & Biological Resarch

TickerCompanyPriceDayMarket cap
ICLRICON plc$191.40-1.67%$14.7B
MEDPMedpace Holdings Inc.$648.20-0.88%$18.1B
INCYIncyte Corp.$120.27-0.58%$24.5B
IQVIQVIA Holdings Inc.$264.73-0.15%$43.6B
ABSIAbsci Corporation$7.47-11.54%$1.3B
OABIOmniAb Inc.$4.89-0.41%$713.3M
NRCNRC Health$26.33-0.87%$558.8M
MXCTMaxCyte Inc.$1.18-0.84%$121.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier